

**Press Release**

**Granules India’s Total Income increases by 18% to INR 1,703 Cr.**

Hyderabad, May 24, 2018: Granules India Ltd., a growing pharmaceutical manufacturing company, announced today financial results for its fourth quarter and financial year ended 31st March, 2018.

(in INR Crs.)

Consolidated Financials	FY 2017-18	Q4 – FY’18
TOTAL INCOME	1,703	513
EBITDA	289	53
PAT	133	20

The Company’s standalone Total Income during the year was INR 1,678 Cr. In this year the Company recorded EBITDA and PAT of INR 317 Cr. and INR 139 Cr. respectively.

The Company’s Board of Directors has proposed a final dividend of 25 paise /share of face value of Rs. 1 each.

“I am happy to share that our full year revenues have shown a steady growth in the currently challenging scenario faced by the sector as a whole. During the year, there were certain macro and industry developments which did not allow our growth in revenue to reflect in profitability, which is attributable to increased cost of materials. Even as there is uncertainty on when these pressures will abate, we are working towards enhancing and strengthening our infrastructure and product portfolio. We continue to improve our regulatory compliance framework and completion of US FDA audits at four of our sites in the last financial year validates our position. We have built capacity and infrastructure to support our business expansion plans and look forward to consolidating our key investments going forward and focus on execution of our strategies.” said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited.



**About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K.

**Contacts:**

Sumanta Bajpayee  
Corporate Finance & Investor Relations  
040-30663572  
sumanta.bajpayee@granulesindia.com

Chaitanya Tummala  
Company Secretary  
040-30663614  
chaitanya.tummala@granulesindia.com

*This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs, and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.*

**GRANULES INDIA LIMITED**  
 Regd Office : 2nd Floor, 3rd Block, My Home Hub  
 Madhapur, Hyderabad 500 081  
 CIN:L24110TG1991PLC012471

Rs in lakhs

**Statement of Consolidated Audited Results for the year ended March 31, 2018**

Sl No.	Particulars	Quarter ended			Year ended	
		31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
		Audited (Refer note-8)	Un-Audited	Audited (Refer note-8)	Audited	Audited
<b>1</b>	<b>Income</b>					
	Revenue from operations (Refer note 4)	50,381.93	41,073.20	36,217.36	1,69,184.83	1,43,525.34
	Other income	967.20	86.38	118.04	1,084.27	992.53
	<b>Total income</b>	<b>51,349.13</b>	<b>41,159.58</b>	<b>36,335.40</b>	<b>1,70,269.10</b>	<b>1,44,517.87</b>
<b>2</b>	<b>Expenses</b>					
	(a) Cost of materials consumed	28,173.47	21,102.43	15,672.30	90,290.48	67,996.46
	(b) Changes in inventories of work in progress and finished goods	2,799.68	(209.73)	(54.60)	(658.34)	(33.28)
	(c) Excise duty on sales	-	-	692.02	722.60	2,468.81
	(d) Employee benefits expense	4,238.52	4,153.06	3,620.90	16,521.21	14,018.97
	(e) Finance costs	620.73	823.41	766.13	3,305.98	3,225.63
	(f) Depreciation/amortisation expense	2,040.52	1,960.08	1,799.95	7,620.20	7,151.27
	(g) Other expenses	10,807.26	8,624.34	8,551.09	34,466.81	29,190.58
	<b>Total expenses</b>	<b>48,680.18</b>	<b>36,453.59</b>	<b>31,047.79</b>	<b>1,52,268.94</b>	<b>1,24,018.44</b>
<b>3</b>	<b>Profit before exceptional items and tax (1-2)</b>	<b>2,668.95</b>	<b>4,705.99</b>	<b>5,287.61</b>	<b>18,000.16</b>	<b>20,499.43</b>
<b>4</b>	<b>Exceptional items</b>	-	-	-	-	-
<b>5</b>	<b>Profit before tax (3-4)</b>	<b>2,668.95</b>	<b>4,705.99</b>	<b>5,287.61</b>	<b>18,000.16</b>	<b>20,499.43</b>
<b>6</b>	<b>Tax expense</b>					
	Current tax	1,427.92	1,528.31	1,336.11	6,593.71	6,607.20
	Deferred tax	(478.10)	161.83	323.00	(253.86)	(87.07)
<b>7</b>	<b>Net Profit after Tax (5-6)</b>	<b>1,719.13</b>	<b>3,015.85</b>	<b>3,628.50</b>	<b>11,660.31</b>	<b>13,979.30</b>
<b>8</b>	<b>Share of Profit of joint venture and associate, net of tax</b>	<b>324.71</b>	<b>485.66</b>	<b>938.87</b>	<b>1,598.81</b>	<b>2,472.61</b>
<b>9</b>	<b>Net Profit for the period (7+8)</b>	<b>2,043.84</b>	<b>3,501.51</b>	<b>4,567.37</b>	<b>13,259.12</b>	<b>16,451.91</b>
	<b>Other Comprehensive income</b>					
	(a) (i) items that will not be reclassified to profit or loss	184.39	-	155.79	184.39	155.79
	(ii) income tax on (i) above	(62.74)	-	(53.92)	(62.74)	(53.92)
	(b) (i) items that will be reclassified to profit or loss	(856.23)	189.54	(79.05)	(741.14)	45.05
	(ii) income tax on (i) above	722.98	-	-	722.98	-
<b>10</b>	<b>Total Other Comprehensive income, net of tax</b>	<b>(11.60)</b>	<b>189.54</b>	<b>22.82</b>	<b>103.49</b>	<b>146.92</b>
<b>11</b>	<b>Total Comprehensive income for the period (9+10)</b>	<b>2,032.24</b>	<b>3,691.05</b>	<b>4,590.19</b>	<b>13,362.61</b>	<b>16,598.83</b>
<b>12</b>	<b>Paid-up equity Share Capital (Face Value of Re.1/- per share)</b>	<b>2,538.38</b>	<b>2,538.18</b>	<b>2,287.03</b>	<b>2,538.38</b>	<b>2,287.03</b>
<b>13</b>	<b>Other equity</b>				<b>1,27,879.21</b>	<b>88,072.51</b>
<b>14</b>	<b>Earnings per Share (Face value Re. 1/- each) (not Annualised)</b>					
	(a) Basic (in Rs.)	0.81	1.38	2.09	5.49	7.52
	(b) Diluted (in Rs.)	0.80	1.38	2.08	5.47	7.48

Statement of Assets and Liabilities :		Rs in lakhs	
Sl.No.	Particulars	As at	As at
		March 31, 2018	March 31, 2017
		(Audited)	(Audited)
<b>A</b>	<b>ASSETS</b>		
	<b>Non-current assets</b>		
	Property, plant and equipment	70,079.04	56,872.54
	Capital work-in-progress	29,007.22	13,025.96
	Other Intangible assets	7,593.92	7,561.30
	Intangible assets under development	22,444.39	13,716.78
	Financial assets		
	Investments	15,655.87	10,822.94
	Loans	1,300.88	-
	Deferred tax assets	695.12	-
	Income tax assets (net)	45.72	237.46
	Other non-current assets	2,243.94	2,589.15
		<b>1,49,066.10</b>	<b>1,04,826.13</b>
	<b>Current assets</b>		
	Inventories	27,994.56	26,917.84
	Financial assets		
	Trade receivables	61,707.73	41,770.02
	Cash and cash equivalents	10,803.28	4,270.15
	Bank balances other than Cash and cash equivalents above	760.34	709.78
	Loans	34.67	158.82
	Others	143.06	247.46
	Other current assets	13,879.24	8,742.34
		<b>1,15,322.88</b>	<b>82,816.41</b>
	<b>Total Assets</b>	<b>2,64,388.98</b>	<b>1,87,642.54</b>
<b>B</b>	<b>Equity and Liabilities</b>		
	<b>Equity</b>		
	Equity share capital	2,538.38	2,287.03
	Other equity	1,27,879.21	88,072.51
	<b>Total equity</b>	<b>1,30,417.59</b>	<b>90,359.54</b>
	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	Financial liabilities		
	Borrowings	43,313.02	12,424.23
	Non-current provisions	770.05	724.95
	Deferred tax liabilities (net)	5,430.88	5,649.86
		<b>49,513.95</b>	<b>18,799.04</b>
	<b>Current liabilities</b>		
	Financial liabilities		
	Borrowings	52,509.95	47,383.30
	Trade payables	25,218.47	21,597.56
	Other financial liabilities	5,000.06	8,376.40
	Other current liabilities	866.64	966.26
	Current tax liabilities (net)	595.19	-
	Short term provisions	267.13	160.44
		<b>84,457.44</b>	<b>78,483.96</b>
	<b>Total Equity and Liabilities</b>	<b>2,64,388.98</b>	<b>1,87,642.54</b>

- 1 The above audited financial results for the quarter and year ended March 31, 2018 have been reviewed by the Audit Committee of the Board on May 23, 2018 and approved by the Board of Directors at their meeting held on May 24, 2018.
- 2 The consolidated audited financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The subsidiaries, joint venture and associate companies considered for the consolidated financial statements as on March 31, 2018 are Granules USA Inc., Granules Pharmaceuticals Inc., Granules Europe Limited (together known as "Subsidiaries") and Hubei Granules Biocause Pharmaceutical Co. Ltd.(known as "associate") and Granules Omnichem Pvt Ltd (known as "joint venture").
- 4 Post implementation of Goods and Service Tax ("GST") with effect from 1 July 2017, revenue from operations is disclosed net of GST. For the periods prior to July 01, 2017, the excise duty amount was recorded as part of revenue with a corresponding amount recorded as expense. Accordingly, revenue from operations for the quarter and year ended March 31, 2018 are not comparable with those of the previous period presented. Following additional information is being provided to facilitate such comparison :

Rs in lakhs

Particulars	Quarter ended			Year ended	
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
i) Revenue from Operations	50,381.93	41,073.20	36,217.36	1,69,184.83	1,43,525.34
ii) Excise duty	-	-	692.02	722.60	2,468.81
iii) Revenue from Operations (i-ii)	50,381.93	41,073.20	35,525.34	1,68,462.23	1,41,056.53

- 5 As per regulation 33 of the Listing Regulations, the Company has opted to publish only consolidated financial results. The standalone financial results are available for perusal at Company's website viz., [www.granulesindia.com](http://www.granulesindia.com) and websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
- 6 The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- 7 During the quarter, the Company has allotted 20,000 equity shares of Re.1/- each, fully paid up on exercise of options by employees in accordance with the Company's Employee Stock Option Scheme(s).
- 8 The figures for the quarters ended March 31, 2018 and March 31, 2017 are the balancing numbers between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which are subjected to limited review.
- 9 The Board of Directors at their meeting held on May 24, 2018 have recommended final dividend of 25 paise per equity share of Re.1/- each in addition to interim dividend of 75 paise per equity share of Re. 1/- each paid during the year.
- 10 Standalone Results for the year ended are as under -

Rs in lakhs

Particulars	Quarter ended			Year ended	
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
	Audited	Un-Audited	Audited	Audited	Audited
Revenue from Operations	47,333.31	41,264.65	35,177.08	1,65,386.92	1,37,416.90
Profit Before Tax	5,135.52	5,063.30	5,484.39	20,845.29	20,680.32
Profit After Tax	3,418.29	3,383.51	3,844.80	13,916.19	14,282.67

for and on behalf of the Board

Place : Hyderabad  
Date : May 24, 2018

Krishna Prasad Chigurupati  
Chairman and Managing Director

**GRANULES INDIA LIMITED**  
 Regd Office : 2nd Floor, 3rd Block, My Home Hub  
 Madhapur, Hyderabad 500 081  
 CIN:L24110TG1991PLC012471

Rs in lakhs

**Statement of Standalone Audited Results for the year ended March 31, 2018**

Sl No.	Particulars	Quarter ended			Year ended	
		31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
		Audited (Refer note-7)	Un-Audited	Audited (Refer note-7)	Audited	Audited
<b>1</b>	<b>Income</b>					
	Revenue from operations (Refer note 3)	47,333.31	41,264.65	35,177.08	1,65,386.92	1,37,416.90
	Other income	1,344.71	411.63	256.02	2,377.13	1,452.02
	<b>Total income</b>	<b>48,678.02</b>	<b>41,676.28</b>	<b>35,433.10</b>	<b>1,67,764.05</b>	<b>1,38,868.92</b>
<b>2</b>	<b>Expenses</b>					
	(a) Cost of materials consumed	27,647.02	21,832.53	15,934.95	89,020.17	67,077.83
	(b) Changes in inventories of work in progress and finished goods	995.36	208.61	(291.34)	1,289.37	(1,220.03)
	(c) Excise duty on sales	-	-	692.02	722.60	2,468.81
	(d) Employee benefits expense	3,815.03	3,803.89	3,222.50	14,792.40	12,581.00
	(e) Finance costs	618.31	816.30	764.41	3,292.70	3,216.41
	(f) Depreciation/ amortisation expense	2,034.54	1,953.23	1,795.65	7,591.64	7,135.16
	(g) Other expenses	8,432.24	7,998.42	7,830.52	30,209.88	26,929.42
	<b>Total expenses</b>	<b>43,542.50</b>	<b>36,612.98</b>	<b>29,948.71</b>	<b>1,46,918.76</b>	<b>1,18,188.60</b>
<b>3</b>	<b>Profit before exceptional items and tax (1-2)</b>	<b>5,135.52</b>	<b>5,063.30</b>	<b>5,484.39</b>	<b>20,845.29</b>	<b>20,680.32</b>
<b>4</b>	<b>Exceptional items</b>	-	-	-	-	-
<b>5</b>	<b>Profit before tax (3-4)</b>	<b>5,135.52</b>	<b>5,063.30</b>	<b>5,484.39</b>	<b>20,845.29</b>	<b>20,680.32</b>
<b>6</b>	<b>Tax expense</b>					
	Current tax	1,443.69	1,536.20	1,295.61	6,389.75	6,362.95
	Deferred tax	273.54	143.59	343.98	539.35	34.70
<b>7</b>	<b>Net Profit after Tax (5-6)</b>	<b>3,418.29</b>	<b>3,383.51</b>	<b>3,844.80</b>	<b>13,916.19</b>	<b>14,282.67</b>
<b>8</b>	<b>Other Comprehensive income</b>					
	(a) (i) items that will not be reclassified to profit or loss	181.30	-	155.79	181.30	155.79
	(ii) income tax on (i) above	(62.74)	-	(53.92)	(62.74)	(53.92)
	(b) (i) items that will be reclassified to profit or loss	(2,068.98)	-	-	(2,068.98)	-
	(ii) income tax on (i) above	722.98	-	-	722.98	-
	<b>Total Other Comprehensive income, net of tax</b>	<b>(1,227.44)</b>	<b>-</b>	<b>101.87</b>	<b>(1,227.44)</b>	<b>101.87</b>
<b>9</b>	<b>Total Comprehensive income for the period (7+8)</b>	<b>2,190.85</b>	<b>3,383.51</b>	<b>3,946.67</b>	<b>12,688.75</b>	<b>14,384.54</b>
<b>10</b>	<b>Paid-up equity Share Capital (Face Value of Re.1/- per share)</b>	<b>2,538.38</b>	<b>2,538.18</b>	<b>2,287.03</b>	<b>2,538.38</b>	<b>2,287.03</b>
<b>11</b>	<b>Other equity</b>				<b>1,25,281.43</b>	<b>86,148.58</b>
<b>12</b>	<b>Earnings per Share (Face value Re. 1/- each) (not Annualised)</b>					
	(a) Basic (in Rs.)	1.35	1.33	1.76	5.76	6.53
	(b) Diluted (in Rs.)	1.34	1.33	1.75	5.74	6.49

Statement of Assets and Liabilities :		Rs in lakhs	
Sl. No.	Particulars	As at	As at
		March 31, 2018	March 31, 2017
		(Audited)	(Audited)
<b>A</b>	<b>Assets</b>		
	<b>Non-current assets</b>		
	Property, plant and equipment	58,854.11	53,057.37
	Capital work-in-progress	27,103.91	12,001.58
	Other Intangible assets	7,161.36	7,500.61
	Intangible assets under development	1,498.71	1,229.31
	Financial assets		
	Investments	7,511.58	7,511.50
	Loans	41,873.88	17,985.29
	Income tax assets(net)	-	466.78
	Other assets	2,026.25	2,394.63
		<b>1,46,029.80</b>	<b>1,02,147.07</b>
	<b>Current assets</b>		
	Inventories	22,735.65	23,758.77
	Financial assets		
	Trade receivables	68,173.67	46,831.27
	Cash and cash equivalents	8,980.94	3,226.70
	Bank balances other than Cash and cash equivalents above	760.34	709.78
	Loans	20.36	139.21
	Others	36.55	25.13
	Other assets	13,808.73	8,658.95
		<b>1,14,516.24</b>	<b>83,349.81</b>
	<b>Total Assets</b>	<b>2,60,546.04</b>	<b>1,85,496.88</b>
<b>B</b>	<b>Equity and Liabilities</b>		
	<b>Equity</b>		
	Equity share capital	2,538.38	2,287.03
	Other equity	1,25,281.43	86,148.58
	<b>Total equity</b>	<b>1,27,819.81</b>	<b>88,435.61</b>
	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	Financial liabilities		
	Borrowings	43,313.02	12,424.24
	Provisions	770.05	724.95
	Deferred tax liabilities (net)	6,281.80	6,402.69
		<b>50,364.87</b>	<b>19,551.88</b>
	<b>Current liabilities</b>		
	Financial liabilities		
	Borrowings	52,509.95	47,383.30
	Trade payables	23,837.87	20,989.67
	Other financial liabilities	4,583.84	8,042.20
	Other liabilities	588.75	933.78
	Income tax liability (net)	573.82	-
	Provisions	267.13	160.44
		<b>82,361.36</b>	<b>77,509.39</b>
	<b>Total Equity and Liabilities</b>	<b>2,60,546.04</b>	<b>1,85,496.88</b>

- 1 The above audited financial results for the quarter and year ended March 31, 2018 have been reviewed by the Audit Committee of the Board on May 23, 2018 and approved by the Board of Directors at their meeting held on May 24, 2018.
- 2 The standalone audited financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 Post implementation of Goods and Service Tax ("GST") with effect from July 01, 2017, revenue from operations is disclosed net of GST. For the periods prior to July 01, 2017, the excise duty amount was recorded as part of revenue with a corresponding amount recorded as expense. Accordingly, revenue from operations for the quarter and year ended March 31, 2018 are not comparable with those of the previous period presented. Following additional information is being provided to facilitate such comparison :

Rs in lakhs

Particulars	Quarter ended			Year ended	
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
i) Revenue from Operations	47,333.31	41,264.65	35,177.08	1,65,386.92	1,37,416.90
ii) Excise duty	-	-	692.02	722.60	2,468.81
iii) Revenue from Operations (i-ii)	47,333.31	41,264.65	34,485.06	1,64,664.32	1,34,948.09

- 4 As per regulation 33 of the Listing Regulations, the Company has opted to publish only consolidated financial results. The standalone financial results are available for perusal at Company's website viz., [www.granulesindia.com](http://www.granulesindia.com) and websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
- 5 The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- 6 During the quarter, the Company has allotted 20,000 equity shares of Re.1/- each, fully paid up on exercise of options by employees in accordance with the Company's Employee Stock Option Scheme(s).
- 7 The figures for the quarters ended March 31, 2018 and March 31, 2017 are the balancing numbers between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which are subjected to
- 8 The Board of Directors at their meeting held on May 24, 2018 have recommended final dividend of 25 paise per equity share of Re.1/- each in addition to interim dividend of 75 paise per equity share of Re. 1/- each paid during the year.

for and on behalf of the Board

Place : Hyderabad  
Date : May 24, 2018

Krishna Prasad Chigurupati  
Chairman and Managing Director